Chemokine Therapeutics Corp., a development-stage company, focuses on the development of peptide-based drugs for human diseases. The company focuses on the area of chemokines, small proteins that regulate various physiological functions primarily in relation to the immune system. Its drug candidates in human clinical trials include CTCE-9908, which is in phase II clinical trials for the treatment of metastasis and angiogenesis cancers; and CTCE-0214 that is in phase I clinical trials stage for hematological support, and for neutrophil, platelet, and stem cell mobilization. The companys other products comprise CTCE-0422, which is in preclinical development stage for wound healing; and CTCE-0324 that is in preclinical development stage for the treatment of peripheral arterial disease in the areas of neovascularization; and CTCE-0501, which is in preclinical development stage for stroke prevention. In addition, it maintains drug discovery programs to identify new drug candidates. The company, formerly known as PTM Molecular Biosystems, Inc., was founded in 1998 and is headquartered in Vancouver, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CHKT